Leading Growth Driver in the Atherosclerosis Drugs Market in 2025: Atherosclerosis Drugs Rise With The Surge In Cardiovascular Diseases Driver's Influence

Which drivers are expected to have the greatest impact on the over the atherosclerosis drugs market's growth?
The anticipated growth of the atherosclerosis drug market is likely due to the increased prevalence of cardiovascular diseases. These ailments usually impact the heart and blood vessels, and atherosclerosis, a condition arising from the accumulation of fats, cholesterol, and other substances on one's artery walls, is usually responsible. Key complications of atherosclerosis include coronary heart disease and stroke. To manage these conditions and prevent complications, atherosclerosis drugs, often aimed at controlling high cholesterol levels and preventing blood clot formation, are used. In September 2024, as data from the Minnesota Department of Health revealed, about 30% of Minnesota's adult population in 2023 recorded high blood pressure. This equates to close to 1.4 million individuals, and by 2022, hypertension-related diseases had resulted in the death of 14,225 residents, accounting for nearly 28% of the state's total deaths. Consequently, the widespread occurrence of cardiovascular diseases is expected to fuel the atherosclerosis drug market.

Get Your Atherosclerosis Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What is the future CAGR of the atherosclerosis drugs market, and how will it impact industry expansion?
The market size for atherosclerosis drugs has been on a consistent rise over the past few years. The market is anticipated to expand from $49.89 billion in 2024 to $51.42 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.1%. The upsurge during the historical period can be credited to factors such as cholesterol management, control of blood pressure, programs to quit smoking, research and development initiatives, and advancements in diagnostics.

Predictions indicate a consistent rise in the atherosclerosis drugs market in the coming years, with an anticipated valuation of $59.38 billion in 2029, representing a compound annual growth rate (CAGR) of 3.7%. Factors contributing to this predicted growth during the forecast period include the development of new therapies, precision medicine, immunotherapy and inflammation, advancements in lipid management, and regulatory support. Significant trends to watch in the forecast period encompass biologic therapies, gene modification and gene treatment, combination therapies, customized treatment strategies, and the incorporation of telemedicine and remote monitoring.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

What are the most significant trends transforming the atherosclerosis drugs market today?
The emergence of innovative products is a noteworthy trend that continues to gain traction in the atherosclerosis drugs market. Market giants in the sector are focusing on the creation of novel drugs and securing approvals to maintain their relevance in the market. Take for an example, in March 2024, Novo Nordisk A/S, a healthcare company based in Denmark, achieved the approval of its novel drug, Wegovy (semaglutide), intended to reduce cardiovascular risk in individuals suffering from obesity or overweight. This drug stands out as the pioneering weight loss medication that is approved to mitigate the risk of crucial cardiovascular incidents in adults burdened with obesity or overweight, and an established cardiovascular disease. This gives a fresh option for treatment to this high-risk demographic. Its dual functionality is crucial in managing obesity but also significantly crucial in thwarting grave cardiovascular issues, which ultimately improves patient prognoses and extends lives.

Which key market segments comprise the atherosclerosis drugs market and drive its revenue growth?
The atherosclerosis drugs market covered in this report is segmented -

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621

What regions are at the forefront of atherosclerosis drugs market expansion?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the atherosclerosis drugs market?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

What Is Covered In The Atherosclerosis Drugs Global Market Report?

• Market Size Forecast: Examine the atherosclerosis drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the atherosclerosis drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the atherosclerosis drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the atherosclerosis drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the atherosclerosis drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the atherosclerosis drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the atherosclerosis drugs market.
• Competitive Landscape: Review strategic developments in the atherosclerosis drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.